Michelle M. Claffey
Pfizer (United States)(US)
Publications by Year
Research Areas
Phosphodiesterase function and regulation, Neuroscience and Neuropharmacology Research, Marine Sponges and Natural Products, Cholinesterase and Neurodegenerative Diseases, Chemical synthesis and alkaloids
Most-Cited Works
- → Selective Inhibition of Casein Kinase 1ϵ Minimally Alters Circadian Clock Period(2009)179 cited
- → Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia(2012)89 cited
- → Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders(2012)71 cited
- → PDE8 Regulates Rapid Teff Cell Adhesion and Proliferation Independent of ICER(2010)69 cited
- → A Method for Constructing the C2−C12 Dispiroacetal Moiety of Altohyrtin A(1996)62 cited
- → Synthesis of the C1−C28 Portion of Spongistatin 1 (Altohyrtin A)(1999)57 cited
- → Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors(2012)55 cited
- → Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 H -pyrazolo-[3,4- b ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator(2014)51 cited
- → Discovery of a novel Kv7 channel opener as a treatment for epilepsy(2015)22 cited
- → Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates(2017)9 cited